Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 38.

Fenn, Gareth, Waller-Evans, Helen, Atack, John R. and Bax, Benjamin D. 2020. Crystallization and structure of ebselen bound to cysteine 141 of human inositol monophosphatase (IMPase). Acta Crystallographica Section F: Structural Biology Communications F76 (10) , pp. 469-476. 10.1107/S2053230X20011310
file

Maramai, Samuele, Benchekroun, Mohamed, Ward, Simon E. and Atack, John R. 2020. Subtype selective y-Aminobutyric acid type A receptor (GABAAR) modulators acting at the benzodiazepine binding site: An update. Journal of Medicinal Chemistry 63 (7) , pp. 3425-3446. 10.1021/acs.jmedchem.9b01312
file

Koulouris, Chloe R., Bax, Benjamin D., Atack, John R. and Roe, S. Mark 2020. Conformational flexibility within the small domain of human serine racemase. Acta Crystallographica Section F: Structural Biology Communications 76 (2) , pp. 65-73. 10.1107/S2053230X20001193
file

Ward, Simon E., Harries, Mark H., Aldegheri, Laura, Bradford, Andrea M., Ballini, Elisa, Dawson, Lee, Lacroix, Laurent, Pardoe, Joanne, Starr, Kathryn, Weil, Annette, Waters, Kerry, Atack, John R. and Woolley, Marie 2020. Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile. Journal of Psychopharmacology 34 (1) , pp. 93-102. 10.1177/0269881119872198
file

Raulin, Ana-Caroline, Kraft, Lucas, Al-Hilaly, Youssra K., Xue, Wei-Feng, McGeehan, John E., Atack, John R. and Serpell, Louise 2019. The molecular basis for apolipoprotein E4 as the major risk factor for late-onset Alzheimer's disease. Journal of Molecular Biology 431 (12) , pp. 2248-2265. 10.1016/j.jmb.2019.04.019
file

Kraft, Lucas, Serpell, Louise C and Atack, John R 2019. A biophysical approach to the identification of novel ApoE chemical probes. Biomolecules 9 (2) , 48. 10.3390/biom9020048
file

Noble, James W., Almalki, Rehab, Roe, S. Mark, Wagner, Armin, Duman, Ramona and Atack, John R. 2018. The X-ray structure of human calbindin-D28K: an improved model. Acta Crystallographica. Section D: Structural Biology 74 (10) , pp. 1008-1014. 10.1107/S2059798318011610
file

Duke, Angela N., Meng, Zhiqiang, Platt, Donna M., Atack, John R., Dawson, Gerard R., Reynolds, David S., Tiruveedhula, V. V. N. Phani Babu, Li, Guanguan, Stephen, Michael Rajesh, Sieghart, Werner, Cook, James M. and Rowlett, James K. 2018. Evidence that sedative effects of benzodiazepines involve unexpected GABAA receptor subtypes: Quantitative observation studies in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 366 (1) , pp. 145-157. 10.1124/jpet.118.249250

Kraft, Lucas, Roe, S. Mark, Gill, Raj and Atack, John R. 2018. Co-crystallization of human inositol monophosphatase with the lithium mimetic L-690,330. Acta Crystallographica. Section D: Structural Biology 74 (10) , p. 973. 10.1107/S2059798318010380
file

West, Ryan A., O'Doherty, Oran G., Askwith, Trevor, Atack, John, Beswick, Paul, Laverick, Jamie, Paradowski, Michael, Pennicott, Lewis E., Rao, Srinivasa P.S., Williams, Gareth and Ward, Simon 2017. African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. European Journal of Medicinal Chemistry 141 , pp. 676-689. 10.1016/j.ejmech.2017.09.067
file

Khan, Raysa, Boonseng, Sarote, Kemmitt, Paul D., Felix, Robert, Coles, Simon J., Tizzard, Graham J., Williams, Gareth, Simmonds, Olivia, Harvey, Jessica-Lily, Atack, John, Cox, Hazel and Spencer, John 2017. Combining Sanford Arylations on Benzodiazepines with the nuisance effect. Advanced Synthesis & Catalysis 359 (18) , pp. 3261-3269. 10.1002/adsc.201700626
file

Hornyak, Peter, Askwith, Trevor, Walker, Sarah, Komulainen, Emilia, Paradowski, Michael, Pennicott, Lewis E., Bartlett, Edward J., Brissett, Nigel C., Raoof, Ali, Watson, Mandy, Jordan, Allan M., Ogilvie, Donald J., Ward, Simon E., Atack, John R., Pearl, Laurence H., Caldecott, Keith W. and Oliver, Antony W. 2016. Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2. Biochemical Journal 473 (13) , pp. 1869-1879. 10.1042/BCJ20160180
file

Gaekens, Tim, Guillaume, Michel, Borghys, Herman, De Zwart, Loeckie L., de Vries, Ronald, Embrechts, Roger C.A., Vermeulen, An, Megens, Anton A.H.P., Leysen, Josée E., Herdewijn, Piet, Annaert, Pieter P. and Atack, John R. 2016. Lipophilic nalmefene prodrugs to achieve a one-month sustained release. Journal of Controlled Release 232 , p. 196. 10.1016/j.jconrel.2016.04.029
file

Spurny, Radovan, Debaveye, Sarah, Farinha, Ana, Veys, Ken, Vos, Ann M., Gossas, Thomas, Atack, John, Bertrand, Sonia, Bertrand, Daniel, Danielson, U. Helena, Tresadern, Gary and Ulens, Chris 2015. Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America 112 (19) , E2543. 10.1073/pnas.1418289112

Atack, John R., Shook, Brian C., Rassnick, Stefanie, Jackson, Paul F., Rhodes, Kenneth, Drinkenburg, Wilhelmus H., Ahnaou, Abdallah, te Riele, Paula, Langlois, Xavier, Hrupka, Brian, De Haes, Patrick, Hendrickx, Herman, Aerts, Nancy, Hens, Koen, Wellens, Annemie, Vermeire, Jef and Megens, Anton A. H. P. 2014. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chemical Neuroscience 5 (10) , pp. 1005-1019. 10.1021/cn5001606

Walker, Sarah, Meisenberg, Cornelia, Bibby, Rachel A., Askwith, Trevor, Williams, Gareth, Rininsland, Frauke H., Pearl, Laurence H., Oliver, Antony W., El-Khamisy, Sherif, Ward, Simon and Atack, John R. 2014. Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Analytical Biochemistry 454 , pp. 17-22. 10.1016/j.ab.2014.03.004
file

Lavreysen, Hilde and Atack, John 2014. Receptors: Functional assays. In: Stolerman, Ian P. and Price, Lawrence H. eds. Encyclopedia of Psychopharmacology, Berlin and Heidelberg: Springer, (10.1007/978-3-642-27772-6_208-2)

Lavreysen, H., Langlois, X., Ahnaou, A., Drinkenburg, W., te Riele, P., Biesmans, I., Van der Linden, I., Peeters, L., Megens, A., Wintmolders, C., Cid, J. M., Trabanco, A. A., Andres, J. I., Dautzenberg, F. M., Lutjens, R., Macdonald, G. and Atack, J. R. 2013. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. Journal of Pharmacology and Experimental Therapeutics 346 (3) , pp. 514-527. 10.1124/jpet.113.204990

Shinday, Nina M, Sawyer, Eileen K, Fischer, Bradford D, Platt, Donna M, Licata, Stephanie C, Atack, John R, Dawson, Gerard R, Reynolds, David S and Rowlett, James K 2013. Reinforcing effects Of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced Rhesus Monkeys. Neuropsychopharmacology 38 (6) , pp. 1006-1014. 10.1038/npp.2012.265

Langlois, X., Megens, A., Lavreysen, H., Atack, J., Cik, M., te Riele, P., Peeters, L., Wouters, R., Vermeire, J., Hendrickx, H., Macdonald, G. and De Bruyn, M. 2012. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 342 (1) , pp. 91-105. 10.1124/jpet.111.190702

Mirza, Naheed R., Atack, John and Wafford, Keith 2012. Receptor subtypes: novel targets for novel medicines. Advances in Pharmacological Sciences 2012 , 529861. 10.1155/2012/529861
file

Swanson, Devin M., Wong, Victoria D., Jablonowski, Jill A., Shah, Chandra, Rudolph, Dale A., Dvorak, Curt A., Seierstad, Mark, Dvorak, Lisa K., Morton, Kirsten, Nepomuceno, Diane, Atack, John R., Bonaventure, Pascal, Lovenberg, Timothy W. and Carruthers, Nicholas I. 2011. The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor. Bioorganic and Medicinal Chemistry Letters 21 (18) , pp. 5552-5556. 10.1016/j.bmcl.2011.06.136

Fischer, Bradford D., Atack, John R., Platt, Donna M., Reynolds, David S., Dawson, Gerard R. and Rowlett, James K. 2011. Contribution of GABAA receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology 215 (2) , pp. 311-319. 10.1007/s00213-010-2142-y

Atack, JR, Wafford, KA, Street, LJ, Dawson, GR, Tye, S, Van Laere, K, Bormans, G, Sanabria-Bohórquez, SM, De Lepeleire, I, de Hoon, JN, Van Hecken, A, Burns, HD, McKernan, RM, Murphy, MG and Hargreaves, RJ 2011. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. Journal of Psychopharmacology 25 (3) , pp. 314-328. 10.1177/0269881109354927

Atack, JR, Hallett, DJ, Tye, S, Wafford, KA, Ryan, C, Sanabria-Bohórquez, SM, Eng, Wai-si, Gibson, RE, Burns, HD, Dawson, GR, Carling, RW, Street, LJ, Pike, A, De Lepeleire, I, Van Laere, K, Bormans, G, de Hoon, JN, Van Hecken, A, McKernan, RM, Murphy, MG and Hargreaves, RJ 2011. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. Journal of Psychopharmacology 25 (3) , pp. 329-344. 10.1177/0269881109354928

Atack, John 2011. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Current Topics in Medicinal Chemistry 11 (9) , pp. 1176-1202. 10.2174/156802611795371350

Atack, John 2011. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Current Topics in Medicinal Chemistry 11 (9) , pp. 1203-1214. 10.2174/156802611795371314

Eng, W., Atack, J.R., Bergstrom, M., Sanabria, S., Appel, L., Dawson, G.R., Sciberras, D., Hargreaves, R.J., Langstrom, B. and Burns, H.D. 2010. Occupancy of human brain GABAA receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [11C]flumazenil PET imaging. Neuropharmacology 59 (7-8) , pp. 635-639. 10.1016/j.neuropharm.2010.07.024

Atack, John R. 2010. Development of subtype-selective GABAA receptor compounds for the treatment of anxiety, sleep disorders and epilepsy. In: Monti, James M., Pandi-Perumal, Seithikurippu Ratnas and Mohler, Hanns eds. GABA and Sleep, Basel: Springer, pp. 25-72. (10.1007/978-3-0346-0226-6_2)

Letavic, Michael A., Aluisio, Leah, Atack, John R., Bonaventure, Pascal, Carruthers, Nicholas I., Dugovic, Christine, Everson, Anita, Feinstein, Mark A., Fraser, Ian C., Hoey, Kenway, Jiang, Xiaohui, Keith, John M., Koudriakova, Tatiana, Leung, Perry, Lord, Brian, Lovenberg, Timothy W., Ly, Kiev S., Morton, Kirsten L., Timothy Motley, S., Nepomuceno, Diane, Rizzolio, Michele, Rynberg, Raymond, Sepassi, Kia and Shelton, Jonathan 2010. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development. Bioorganic and Medicinal Chemistry Letters 20 (14) , pp. 4210-4214. 10.1016/j.bmcl.2010.05.041

Stocking, Emily M., Aluisio, Leah, Atack, John R., Bonaventure, Pascal, Carruthers, Nicholas I., Dugovic, Christine, Everson, Anita, Fraser, Ian, Jiang, Xiaohui, Leung, Perry, Lord, Brian, Ly, Kiev S., Morton, Kirsten L., Nepomuceno, Diane, Shah, Chandravadan R., Shelton, Jonathan, Soyode-Johnson, Akinola and Letavic, Michael A. 2010. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters 20 (9) , pp. 2755-2760. 10.1016/j.bmcl.2010.03.071

Dixon, C. I., Morris, H. V., Breen, G., Desrivieres, S., Jugurnauth, S., Steiner, R. C., Vallada, H., Guindalini, C., Laranjeira, R., Messas, G., Rosahl, T. W., Atack, J. R., Peden, D. R., Belelli, D., Lambert, J. J., King, S. L., Schumann, G. and Stephens, D. N. 2010. Cocaine effects on mouse incentive-learning and human addiction are linked to α2 subunit-containing GABAA receptors. Proceedings of the National Academy of Sciences 107 (5) , pp. 2289-2294. 10.1073/pnas.0910117107

Licata, Stephanie C., Platt, Donna M., Rüedi-Bettschen, Daniela, Atack, John R., Dawson, Gerard R., Van Linn, Michael L., Cook, James M. and Rowlett, James K. 2010. Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABAA receptor subtypes. Neuropharmacology 58 (2) , pp. 357-364. 10.1016/j.neuropharm.2009.10.004

Shoblock, James R., Welty, Natalie, Nepomuceno, Diane, Lord, Brian, Aluisio, Leah, Fraser, Ian, Motley, S. Timothy, Sutton, Steve W., Morton, Kirsten, Galici, Ruggero, Atack, John R., Dvorak, Lisa, Swanson, Devin M., Carruthers, Nicholas I., Dvorak, Curt, Lovenberg, Timothy W. and Bonaventure, Pascal 2010. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor. Psychopharmacology 208 (2) , pp. 265-277. 10.1007/s00213-009-1726-x

Atack, John R. 2010. Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA. Pharmacology and Therapeutics 125 (1) , pp. 11-26. 10.1016/j.pharmthera.2009.09.001

Atack, J. R., Wong, D. F., Fryer, T. D., Ryan, C., Sanabria, S., Zhou, Y., Dannals, R. F., Eng, W.-s., Gibson, R. E., Burns, H. D., Vega, J. M., Vessy, L., Scott-Stevens, P., Beech, J. S., Baron, J.-C., Sohal, B., Schrag, M. L., Aigbirhio, F. I., McKernan, R. M. and Hargreaves, R. J. 2010. Benzodiazepine binding site occupancy by the Novel GABAA receptor subtype-selective drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. Journal of Pharmacology and Experimental Therapeutics 332 (1) , pp. 17-25. 10.1124/jpet.109.157909

Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D. and Dawson, G. R. 2010. Reducing abuse liability of GABAA/Benzodiazepine ligands via selective partial agonist efficacy at α1 and α2/3 subtypes. Journal of Pharmacology and Experimental Therapeutics 332 (1) , pp. 4-16. 10.1124/jpet.109.158303

Atack, John R. 2009. GABAA receptor α2/α3 subtype-selective modulators as potential nonsedating anxiolytics. Current Topics in Behavioral Neuroscience 2 , pp. 331-360. 10.1007/7854_2009_30

This list was generated on Tue Dec 1 04:25:40 2020 GMT.


Maintained by Cardiff University Information Services